
China's cell and gene therapy trials outside the drug regulator grew 11-fold from 2015 to 2023, reaching 207 before Order 818 took effect in 2026
Cell and gene therapy trials outside China's drug regulator grew roughly eleven-fold between 2015 and 2023, peaking near 207 studies a year before two child deaths and State Council Order 818 forced Beijing to tighten oversight.















